Nine articles appeared about Surgery Partners in a single day, nearly all explaining the same thing: shares surged after a report said buyers had agreed to take the surgical-centre operator private in a deal valued at $5.7 billion, with a report citing a $6 billion figure and a report describing the stock as having skyrocketed nearly 50%.
Whatever purchase terms eventually reach a filing will land in a future 8-K, not in the trailing-twelve-month figures examined here. So the more answerable question isn’t what the deal is worth. It’s what kind of company is being bought.
Cash is growing more slowly than profit
Over the twelve months through the June quarter, Surgery Partners’ free cash flow grew 7.0% year over year to $187.6m. Net income over the same period rose 50.9%, moving from a larger loss to a smaller one, but it remained negative at -$88.6m. The two measures describe different things: free cash flow is money the business generated and kept after paying for its own equipment, while net income carries non-cash charges that can swing faster than cash itself. A net margin of -2.6% sits alongside a free cash flow margin of 5.6%, a positive figure built on a trailing operating cash flow of $258.0m against capital expenditure of $70.4m.
| Metric (TTM through FY2026 Q2) | Value |
|---|---|
| Revenue | $3.4 billion |
| Revenue growth, YoY | 4.0% |
| Operating margin | 11.4% |
| Net margin | -2.6% |
| Free cash flow | $187.6m |
| Free cash flow growth, YoY | 7.0% |
| Net income | -$88.6m |
| Net income growth, YoY | 50.9% |
| Capital expenditure | $70.4m |
| Capex growth, YoY | fell 20.5% |
Revenue growth has slowed for five straight quarters
Trailing revenue reached $3.4 billion for the twelve months through June, up 4.0% year over year. Operating margin held relatively steady at 11.4%, up 0.2 percentage points year over year. Capital spending fell 20.5% to $70.4m, equal to 2.1% of revenue, while operating cash flow of $258.0m was down 2.2% year over year even as free cash flow rose, because the capex reduction did more of the work than the operating cash line did. For a buyer paying a fixed price for future cash flows, a growth rate’s direction over several quarters tends to matter as much as its current level.
The other reading
None of this requires reading the business as deteriorating. A slower but still positive revenue growth rate, a stable operating margin and a narrowing net loss are also consistent with a company settling into steadier, lower-growth economics after a period of faster expansion, a profile some acquirers prefer precisely because it is less volatile than high-growth assets. The diluted share count rose 1.3% year over year; the filings describe that change without attributing a cause. What the filings cannot say is why a buyer would settle on $5.7 billion, $6 billion, or any other figure in this week’s reporting, since that calculation rests on assumptions about future growth and margins that sit outside the trailing twelve months of filed data.
Does a 5.6% FCF margin justify Surgery Partners’ price tag?
Our discounted cash flow model for Surgery Partners is built from trailing free cash flow and a forward growth assumption, the same two inputs this week’s deal reporting leaves unaddressed. The free cash flow margin, 5.6% of revenue over the trailing twelve months, determines how much of each additional sales dollar turns into free cash flow in the model; the revenue growth rate, 4.0% over the same period, determines how many future dollars there are to convert. This quarter’s filings show those two inputs moving in different directions: margin edged up while growth decelerated for a fifth straight quarter. The filings do not include a sensitivity breakdown showing which of the two inputs would move modelled value by more. These are model values under stated assumptions, not a comparison with the share price.